(BIOA) BioAge Labs - Overview
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NASDAQ (USA) | Market Cap: 720m USD | Total Return: 334.4% in 12m
Avg Turnover: 6.00M
Qual. Beats: 0
Warnings
Share dilution 18.5% YoY
High Debt while negative Cash Flow
Interest Coverage Ratio -192.5 is critical
Beneish M-Score 0.25 > -1.5 - likely earnings manipulation
Altman Z'' -15.00 < 1.0 - financial distress zone
Tailwinds
Rs Leader, Idiosyncratic Leader, Confidence
BioAge Labs, Inc. (BIOA) is a clinical-stage biopharmaceutical firm focused on developing therapies for metabolic diseases by leveraging human longevity datasets. The company utilizes a proprietary technology platform to identify molecular drivers of aging, translating these insights into a pipeline of small-molecule and agonist candidates. Its lead programs include BGE-102, an NLRP3 inhibitor targeting cardiovascular and retinal diseases, and APJ agonists currently being developed for obesity management.
The company operates within the biotechnology sector, where value is primarily driven by clinical trial progression and intellectual property milestones rather than immediate revenue. BioAge utilizes a partnership-heavy business model, exemplified by its collaboration with Novartis Pharma AG to validate novel drug targets. This approach allows clinical-stage firms to offset high research and development costs while gaining access to established pharmaceutical infrastructure.
Investors can further evaluate the companys clinical pipeline and valuation metrics through the data available on ValueRay.
Incorporated in 2015 and based in Emeryville, California, BioAge Labs focuses on the intersection of metabolic health and the biological mechanisms of aging. By targeting the APJ and NLRP3 pathways, the company aims to address large-addressable markets in obesity and chronic inflammation.
- Clinical trial results for BGE-105 determine viability in the competitive obesity market
- Success of NLRP3 inhibitor Phase 1 trials impacts cardiovascular disease pipeline valuation
- Collaboration milestones with Novartis provide essential non-dilutive funding and validation
- FDA regulatory hurdles for aging-related metabolic therapies influence long-term market entry
- High research and development expenses necessitate future capital raises and equity dilution
| Net Income: -89.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.22 > 0.02 and ΔFCF/TA -6.58 > 1.0 |
| NWC/Revenue: 3.65k% < 20% (prev 20.7k%; Δ -17.1k% < -1%) |
| CFO/TA -0.22 > 3% & CFO -88.3m > Net Income -89.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 24.76 > 1.5 & < 3 |
| Outstanding Shares: last quarter (42.5m) vs 12m ago 18.49% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 2.78% > 50% (prev 0.42%; Δ 2.36% > 0%) |
| Interest Coverage Ratio: -192.5 > 6 (EBITDA TTM -92.4m / Interest Expense TTM 481k) |
| A: 0.95 (Total Current Assets 391.9m - Total Current Liabilities 15.8m) / Total Assets 397.7m |
| B: -0.89 (Retained Earnings -355.7m / Total Assets 397.7m) |
| C: -0.25 (EBIT TTM -92.6m / Avg Total Assets 370.7m) |
| D: -19.19 (Book Value of Equity -355.6m / Total Liabilities 18.5m) |
| Altman-Z'' = -18.54 = D |
| DSRI: 0.28 (Receivables 709k/361k, Revenue 10.3m/1.45m) |
| GMI: 1.02 (GM 97.94% / 100.0%) |
| AQI: 0.12 (AQ_t 0.01 / AQ_t-1 0.04) |
| SGI: 7.11 (Revenue 10.3m / 1.45m) |
| TATA: -0.00 (NI -89.9m - CFO -88.3m) / TA 397.7m) |
| Beneish M = 0.25 (Cap -4..+1) = D |
As of May 30, 2026, the stock is trading at USD 17.29 with a total of 234,018 shares traded.
Over the past week, the price has changed by +3.29%,
over one month by +2.55%,
over three months by -22.36% and
over the past year by +334.42%.
BioAge Labs has received a consensus analysts rating of 2.50. Therefore, it is recommended to sell BIOA.
- StrongBuy: 0
- Buy: 0
- Hold: 3
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 51.4 | 197.5% |
P/S = 69.8075
P/B = 1.896
Revenue TTM = 10.3m USD
EBIT TTM = -92.6m USD
EBITDA TTM = -92.4m USD
Long Term Debt = 2.23m USD (estimated: total debt 4.03m - short term 1.80m)
Short Term Debt = 1.80m USD (from shortTermDebt, last quarter)
Debt = 6.91m USD (from shortLongTermDebtTotal, last quarter) + Leases 2.88m
Net Debt = -376.3m USD (calculated: Debt 6.91m - CCE 383.2m)
Enterprise Value = 343.8m USD (720.1m + Debt 6.91m - CCE 383.2m)
Interest Coverage Ratio = -192.5 (Ebit TTM -92.6m / Interest Expense TTM 481k)
EV/FCF = -3.88x (Enterprise Value 343.8m / FCF TTM -88.6m)
FCF Yield = -25.78% (FCF TTM -88.6m / Enterprise Value 343.8m)
FCF Margin = -859.1% (FCF TTM -88.6m / Revenue TTM 10.3m)
Net Margin = -871.8% (Net Income TTM -89.9m / Revenue TTM 10.3m)
Gross Margin = unknown ((Revenue TTM 10.3m - Cost of Revenue TTM 213k) / Revenue TTM)
Tobins Q-Ratio = 0.86 (Enterprise Value 343.8m / Total Assets 397.7m)
Interest Expense / Debt = 6.96% (Interest Expense 481k / Debt 6.91m)
Taxrate = 21.0% (US default 21%)
NOPAT = -73.2m (EBIT -92.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 24.76 (Total Current Assets 391.9m / Total Current Liabilities 15.8m)
Debt / Equity = 0.02 (Debt 6.91m / totalStockholderEquity, last quarter 379.1m)
Debt / EBITDA = 4.07 (negative EBITDA) (Net Debt -376.3m / EBITDA -92.4m)
Debt / FCF = 4.25 (negative FCF - burning cash) (Net Debt -376.3m / FCF TTM -88.6m)
Total Stockholder Equity = 305.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -24.26% (Net Income -89.9m / Total Assets 397.7m)
RoE = -13.59% (Net Income TTM -89.9m / Total Stockholder Equity 661.5m)
RoCE = -13.95% (EBIT -92.6m / Capital Employed (Equity 661.5m + L.T.Debt 2.23m))
RoIC = -28.79% (negative operating profit) (NOPAT -73.2m / Invested Capital 254.1m)
WACC = 11.65% (E(720.1m)/V(727.0m) * Re(11.71%) + D(6.91m)/V(727.0m) * Rd(6.96%) * (1-Tc(0.21)))
Discount Rate = 11.71% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 79.50 | Cagr: 10.12%
[DCF] Fair Price = unknown (Cash Flow -88.6m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.05 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.61 | Chg30d=+5.08% | Revisions=+25% | Analysts=4
EPS next Quarter (2026-09-30): EPS=-0.61 | Chg30d=+5.45% | Revisions=+0% | Analysts=4
EPS current Year (2026-12-31): EPS=-2.35 | Chg30d=+9.69% | Revisions=+25% | GrowthEPS=-4.8% | GrowthRev=+560.5%
EPS next Year (2027-12-31): EPS=-2.71 | Chg30d=+2.40% | Revisions=+25% | GrowthEPS=-15.4% | GrowthRev=-69.5%
[Analyst] Revisions Ratio: +25%